JSKN016 before surgery for stage II-III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called JSKN016 given before surgery to shrink tumors in people with stage II or III non-small cell lung cancer. It aims to see if the drug is safe and helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stage II, IIIA, or IIIB non-small cell lung cancer that can be removed with surgery.
- You have not had any prior cancer treatment like chemotherapy, radiation, or targeted therapy.
- Your tumor does not have certain common mutations (EGFR or ALK).
- You have good organ function (heart, lungs, liver, kidneys, bone marrow) and are healthy enough for surgery.
- Women who could get pregnant or men with partners who could get pregnant must use effective birth control during and for 24 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial tests a new drug called JSKN016 for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments. It may help those with certain gene changes or after prior therapy has failed.
Hear when a new NSCLC Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.